 |
市場調査レポート
商品コード
1360364
メディカルアフェアーズアウトソーシングの世界市場 - 市場規模、シェア、成長分析：サービス別（医療モニタリング、メディカルライティング・出版）、業界別（医療機器、製薬・バイオ医薬品） - 業界予測（2023年～2030年）Global Medical Affairs Outsourcing Market Size, Share, Growth Analysis, By Services(Medical Monitoring, Medical Writing & Publishing), By Industry(Medical Devices and Pharma & biopharmaceuticals) - Industry Forecast 2023-2030 |
||||||
| メディカルアフェアーズアウトソーシングの世界市場 - 市場規模、シェア、成長分析：サービス別（医療モニタリング、メディカルライティング・出版）、業界別（医療機器、製薬・バイオ医薬品） - 業界予測（2023年～2030年） |
|
出版日: 2023年09月21日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
世界のメディカルアフェアーズアウトソーシングの市場規模は、2021年に14億9,000万米ドルと評価され、予測期間（2023年～2030年）のCAGRは13.6%と見込まれており、2022年の17億米ドルから2030年には47億1,000万米ドルに成長する見通しです。
世界のメディカルアフェアーズアウトソーシング市場は、感染症および非感染症の蔓延による臨床試験の顕著な増加を背景に、大きく拡大しつつあります。このような臨床活動の急増は、医療機器や革新的な医薬品の需要を急増させ、医療アウトソーシングソリューションの必要性を高めています。
さらに、この市場成長は、開発業務受託機関が提供するコスト効率と一流のサービスの魅力的な融合によって後押しされています。また、厳しい規制の存在も専門的な熟練度の必要性を強調し、市場の見通しをさらに強固なものにしています。
これらの要因が総合的に、メディカルアフェアーズアウトソーシング分野の発展に寄与する環境を醸成しています。世界の大流行の影響は、メディカルアフェアーズアウトソーシングを含むさまざまな業界に波及しています。
規制当局やアウトソーシング部門が直面するハードルにもかかわらず、COVID-19の発生は、メディカルアフェアーズにおける製薬業界の専門家のルーチンの転換を必要としました。この調整により、バーチャルな科学的関与が急増し、科学的コミュニケーションが重視されるようになっています。長期的には、このような変革はメディカルアフェアーズチームの構成と職務を再形成すると予測されます。
特定の医療チャネルを通じた先進治療へのアクセスの促進、患者グループとの積極的な関わり、専門医療における極めて重要な役割など、新たな領域がメディカルアフェアーズの領域に不可欠な要素となることが想定されます。
医薬品や医療機器の分野は、価格設定の制約、厳しい規制、特許切れといった課題に直面し、利益率の低下を招いています。メディカルアフェアーズ業務の受託は、主にコスト削減効果により、バイオ医薬品や製薬企業の間で戦略的かつ競争力のある手段として台頭してきています。
製薬・医療機器企業は、CRO（医薬品開発業務受託機関）にメディカルアフェアーズ業務を委託することで、業務経費の削減、法的責任の軽減、規制遵守の強化、手続き上のボトルネックの回避などを、優れたアウトソーシング先とのパートナーシップを通じて実現することができます。この傾向は、企業が機能の最適化を図り、厳しい企業環境を乗り切ろうと努力する中で、今後も続くとみられています。
ヘルスケアの分野では、製品の有効性と安全性を立証する具体的なエビデンスに対する需要が高まっています。その中で、メディカルアフェアーズアウトソーシングのプロバイダーは、実データを作成、評価、配布するという極めて重要な役割を担っています。このデータは、医薬品や医療機器の信頼性を高める役割を果たします。
当レポートは、世界のメディカルアフェアーズアウトソーシング市場について調査し、市場の概要とともに、サービス別、業界別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。
目次
エグゼクティブサマリー
親市場分析
市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主要な市場の洞察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 動向分析
- スタートアップ分析
- 原材料分析
- イノベーションマトリックス
- パイプライン製品分析
- マクロ経済指標
- トップ投資分析
- 主な成功要因
- 競合の程度
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制状況
- ポーター分析
世界のメディカルアフェアーズアウトソーシング市場、サービス別
- 市場概要
- 医療モニタリング
- メディカルライティング・出版
- 医療情報
- メディカルサイエンスリエゾン
- その他
世界のメディカルアフェアーズアウトソーシング市場、業界別
- 市場概要
- 医療機器、製薬・バイオ医薬品
世界のメディカルアフェアーズアウトソーシング市場、地域別
- 市場概要
- 北米
- 欧州
- アジア太平洋
- ラテンアメリカ
- 中東・アフリカ
競合情勢
- 主要企業プロファイル
- IQVIA Inc.
- Syneos Health Inc.
- PAREXEL International Corporation
- ICON plc
- PPD社
- Pharmaceutical Product Development, LLC（PPD）
- Covance Inc
- PRA Health Sciences, Inc.
- Medpace Holdings, Inc.
- Charles River Laboratories International, Inc.
- ProPharma Group
- The Medical Affairs Company, LLC
- Indegene, Inc
- Ashfield Healthcare Communications Group
- Accenture plc
- MMS Holdings Inc.
- Clinipace Worldwide
- Max Neeman International
- Freyr Solutions
- Comprehend Systems, Inc.
Global Medical Affairs Outsourcing Market size was valued at USD 1.49 billion in 2021 and is poised to grow from USD 1.7 billion in 2022 to USD 4.71 billion by 2030, at a CAGR of 13.6% during the forecast period (2023-2030).
The global market for outsourcing medical affairs is undergoing significant expansion, driven by a notable increase in clinical trials due to the growing prevalence of communicable and non-communicable diseases. This surge in clinical activity has spiked demand for medical devices and innovative drugs, thereby intensifying the necessity for medical outsourcing solutions.
Furthermore, this market growth is propelled by the appealing amalgamation of cost-efficiency and top-notch services offered by contract research organizations. The presence of strict regulatory demands also underscores the requirement for specialized proficiency, further fortifying the market's prospects.
These factors collectively foster an environment conducive to the progression of the medical affairs outsourcing sector. The widespread effects of the global pandemic have reverberated across various industries, including medical affairs outsourcing.
Despite the hurdles confronted by regulatory and outsourcing units, the outbreak of COVID-19 has necessitated a shift in the routines of pharmaceutical industry professionals in medical affairs. This adjustment has given rise to a considerable surge in virtual scientific engagements and an elevated emphasis on scientific communication. In the long run, these transformations are predicted to reshape the configuration and duties of medical affairs teams.
Emergent domains, such as facilitating access to advanced treatments through specific healthcare channels, active engagement with patient groups, and pivotal roles in specialty care, are envisioned to become integral facets of the medical affairs realm.
Pharmaceutical and medical device sectors confront challenges like pricing constraints, rigorous regulations, and patent expirations, leading to narrowed profit margins. Contract medical affairs services are emerging as a strategic and competitive instrument among biopharmaceutical and pharmaceutical enterprises, primarily due to the cost-saving benefits they provide.
By delegating medical affairs services to contract research organizations (CROs), pharmaceutical and medical device companies can curtail operational expenses, mitigate liability exposure, enhance compliance with regulations, and avert procedural bottlenecks through partnerships with adept outsourcing collaborators. This inclination is likely to persist as businesses strive to optimize their functions and navigate the demanding corporate landscape.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Medical Affairs Outsourcing Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Driver
The healthcare sector's demand for tangible evidence to substantiate the effectiveness and safety of products is on the rise. In this context, providers of medical affairs outsourcing assume a pivotal role in producing, evaluating, and distributing real-world data. This data serves to bolster the credibility of pharmaceutical products and medical devices.
Restraint
Delegating medical affairs responsibilities externally can present obstacles in upholding uniform quality and ensuring alignment with internal benchmarks and regulatory mandates. To effectively address these challenges, organizations need to establish robust frameworks for oversight and evaluation.
Market Trends
The demand for real-world evidence is on a steady rise among pharmaceutical and medical device firms, as they seek to establish the effectiveness, safety, and value of their products. In this context, medical affairs outsourcing entities are assuming a pivotal role in the generation and analysis of real-world data. This support aids companies in making informed decisions grounded in evidence and facilitates the compilation of regulatory submissions.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
- Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
- Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
- Global Medical Affairs Outsourcing Market by Services
- Market Overview
- Medical Monitoring
- Medical Writing & Publishing
- Medical Information
- Medical Science Liaisons
- Others
- Global Medical Affairs Outsourcing Market by Industry
- Market Overview
- Medical Devices and Pharma & biopharmaceuticals
- Global Medical Affairs Outsourcing Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
- Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
- Key Company Profiles
- IQVIA Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Syneos Health Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PAREXEL International Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- ICON plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PPD, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pharmaceutical Product Development, LLC (PPD) (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Covance Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PRA Health Sciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Medpace Holdings, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Charles River Laboratories International, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- ProPharma Group (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- The Medical Affairs Company, LLC (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Indegene, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ashfield Healthcare Communications Group (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Accenture plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- MMS Holdings Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Clinipace Worldwide (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Max Neeman International (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Freyr Solutions (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Comprehend Systems, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
